Immediate Impact
16 standout
Citing Papers
Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis
2024 Standout
Myasthenia gravis: the changing treatment landscape in the era of molecular therapies
2024 Standout
Works of Benison Keung being referenced
Durability of the Rituximab Response in Acetylcholine Receptor Autoantibody–Positive Myasthenia Gravis
2016
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Benison Keung | 79 | 7 | 34 | 6 | 85 | |
| Luis González‐Gutiérrez‐Solana | 44 | 8 | 20 | 8 | 92 | |
| Tarin A. Europa | 71 | 3 | 24 | 6 | 80 | |
| August Jernbom Falk | 23 | 4 | 18 | 6 | 67 | |
| Humberto Ibarguen Salazar | 47 | 4 | 14 | 9 | 82 | |
| Riley D Herriman | 51 | 4 | 15 | 5 | 183 | |
| Wilfried Schenk | 57 | 11 | 14 | 4 | 82 | |
| Manlio Sgarzi | 47 | 7 | 6 | 8 | 57 | |
| Clare Miller | 24 | 8 | 33 | 6 | 70 | |
| Harmesh Moudgil | 89 | 3 | 77 | 5 | 104 | |
| Robert H.P. de Meel | 157 | 6 | 45 | 11 | 172 |
All Works
Login with ORCID to disown or claim papers
Loading papers...